Finding the Answer to
Treating COVID
Thinking Through the Process
Corona viruses are known for having spiked extensions protruding from the virus itself - giving the appearance of a crown - i.e. corona.
​
Each virus has an affinity for a different part of the body - although this does not mean this is the only place the virus will be found. SARS-CoV-2, the actual virus causing an InflammoThrombotic Immunologic Response (ITIR) Disease (ITIRD) known as COVID, has an affinity for the pulmonary (lungs) and gastrointestinal (GI tract) system.
This tendency to target the lungs and GI tract accounts for many of the symptoms and deaths resulting from the accumulation of the ITIR material in the airways of the lungs, resulting in fluid building up in the areas of the lungs where oxygen (O2) and carbon dioxide (CO2) are exchanged (the alveoli); resulting in a sudden failure (acute respiratory distress syndrome; ARDS) to receive adequate oxygen to keep us alive.
​
The resulting ITIR explains the increased morbidity and mortality including heart attacks, strokes, blood clots, et cetera.
​
As demonstrated previously in the Bacterially Aggravated Atherosclerosis (BAA) research I published, this is not unique to COVID viruses. The BAA research not only demonstrated increased heart disease and thymic activity; but, also increased levels of interleukin-6 (IL-6) and other markers of an ITIR.
​
What the BAA studies also taught us, is that correct treatment of these infections (bacteria, viral, et cetera), can stop and in some instances restore the ITIR damage caused in the heart, lungs and elsewhere in the body.
​
Therefore, determining which treatments work and which do not, is not only critical to reduce or prevent the harm caused to those infected; but, to potentially help those who have become critically ill with the ITIRD - COVID.
​
Both the COVID virus and the ITIRD caused by COVID - as well as we would later learn, the COVID genetic vaccines - produce changes in regional blood flow and metabolism, which can be measured by FMTVDM.
These FMTVDM measurements can determine both (1) the severity of the infection and ITIRD response and (2) the theranostic measurement and thus determination of which treatments work and which do not.
Establishing FMTVDM Across Multiple Study Sites
As previously discussed, quantitatively calibrating the nuclear imaging cameras is dependent upon what you are looking for and what type of nuclear camera & isotope you are using.
​
With this information in hand, you can quantitatively calibrate the nuclear cameras to carry out the diagnostic and/or research study you are trying to obtain answers to, including measurements of treatment success - or failure.
​
Carrying out a multicenter clinical research trial requires the consideration of many factors including but not limited to the following:
​
​1) Concerns with transporting COVID patients,
2) Availability of isotopes,
3) Ability to virtually teach and train nuclear technologists,
4) Available personal protective equipment (PPE) and procedures,
5) Availability of equipment to standardize outcomes, and
6) Transfer and safety of data.
​
Given these factors, I elected to use planar (static) imaging cameras, which would provide the following types of quantitative measurements using the FMTVDM protocol designed for this study.
These measurements included corona virus pneumonia (CVP) and measurement of thymus activity.
​
The following graphic shows the range [150 MCA - 260 MCA] of expected maximum count activity (MCA) using Technetium-99m agents, using planar (mobile) imaging, to measure the regional blood flow and metabolic activity of an infection producing an InflammoThrombotic Immunologic Response (ITIR) Disease (IRITD) process - i.e. COVID.
Selecting Treatment Options for COVID
Just because someone doesn't die, or someone gets better, doesn't mean the improvement in their health was the result of the treatment given to them.
​
Too often people promote treatments without verification - proof - that what they did for the person was the reason the person got better. People might get better without treatment, or they might get better despite the treatment.
​
Scientific evidence has shown us that drugs only work 10-20% of the time we think they will work - some times less.
Selection of potential drug candidates for the treatment of the SARS-CoV-2 viruses and the ITIRD - COVID - were made based upon published research showing mechanisms of action expected to work in the treatment of the virus and resulting ITIRD - COVID.
​
Based upon the published [https://www.flemingmethod.com/documentation] demonstrated mechanisms of action, the following treatments were selected for inclusion in the study and are shown in the following tables.
Additional treatments for immune support, respiratory support and thrombosis (blood clot) prophylaxis included in this study are shown in the following slide.
Upon selection for inclusion in the study, participants began in the outpatient setting, as shown in the red enclosed region of the following graphic.
Following outcomes of outpatient treatment, 501 individuals were admitted to hospital for further care and were randomized to one of the following treatment arms (different treatments) as shown in the following graphic.​
FMTVDM measurements were made every 3-days to determine the effect of treatment.
Patients remained on their current treatment when FMTVDM measurements showed improvement.
When FMTVDM measurements showed lack of benefit or worsening of health status, another treatment was randomly selected and added to the prior treatment.
​
This process continued until treatment combinations were either successful or the patient expired.
​
An example of this process is shown in the following slide, where the patient received hydroxychloroquine (HCQ) as their initial treatment. At 3-days FMTVDM measurement showed the HCQ failed to work.
​
Methylprednisolone was then added to the treatment regimen.
RESULTS
For outpatients enrolled in this study the following treatment results were reported.
The following treatment results were reported for hospital inpatients.
This research study, not only showed that SARS-CoV-2 and COVID can be successfully treated, but that the success of that treatment was demonstrated using FMTVDM imaging protocol and measurements.
​
Taken in conjunction with the Bacterially Aggravated Atherosclerosis (BAA) research, this COVID research, demonstrates that like heart disease and cancer, FMTVDM measurement provides both diagnostic and theranostic (treatment) benefit in the treatment of infectious diseases.